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BACKGROUND: In most Western populations, 5–10% of all breast cancer cases can be attributed to major genetic factors such as
predisposing mutations in BRCA1 and BRCA2, with early-onset cases generally considered as an indicator of genetic susceptibility.
Specific BRCA1 and BRCA2 mutations or different mutation frequencies have been identified in specific populations and ethnic groups.
Previous studies in Greek breast and/or ovarian cancer patients with family history have shown that four specific BRCA1 mutations,
c.5266dupC, G1738R, and two large genomic rearrangements involving deletions of exons 20 and 24, have a prominent function in
the population’s BRCA1 and BRCA2 mutation spectrum.
METHODS: To estimate the frequency of the above mutations in unselected Greek breast cancer women, we screened 987 unselected
cases independently of their family history, collected from major Greek hospitals.
RESULTS: Of the 987 patients, 26 (2.6%) were found to carry one of the above mutations in the BRCA1 gene: 13 carried the
c.5266dupC mutation (1.3%), 6 carried the exon 24 deletion (0.6%), 3 carried the exon 20 deletion (0.3%), and 4 carried the
G1738R mutation (0.4%). Among 140 patients with early-onset breast cancer (o40 years), 14 carried one of the four mutations
(10.0%).
CONCLUSION: These results suggest that a low-cost genetic screening for only the four prominent BRCA1 mutations may be advisable
to all early-onset breast cancer patients of Greek origin.
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Breast cancer is the most common malignancy in women, affecting
approximately 1 in 10 women. Incidence rates are increasing
annually and it is estimated that by year 2010 there will be 1.5
million new cases worldwide (Parkin et al, 2005). Germ-line
mutations in predisposing genes, mainly BRCA1 (MIM 113705)
and BRCA2 (MIM 600185) but also other genes critical for genome
integrity such as CHEK2, PALB2, ATM, p53, PTEN, STK11, CDH1
and more, are responsible for about half of familial breast cancer
cases, which in turn represent one-third of all breast cancers
(Walsh and King, 2007). Mutations are often found in families
burdened with many cases of breast and/or ovarian cancer, usually
occurring at an earlier age. Assessing an at-risk individual’s
mutation status is a procedure growing in clinical importance from
an optional genetic test to a powerful predictive tool, as prevention
protocols for carriers become established and new treatment
options emerge (Robson and Offit, 2007; De Greve et al, 2008).
However, full BRCA1 and BRCA2 screening still remains a tedious
task due to gene length, the plethora of mutations, the high
frequency of BRCA1 rearrangements requiring special technical
approach, and mutation spectrum differences in different popula-
tions. This procedure remains too expensive to target a broader
population part and cannot be routinely applied in less privileged
areas and countries.
Several studies have shown that in certain countries and ethnic
communities the BRCA1 and BRCA2 mutation spectrum is limited
to a few founder mutations (Neuhausen, 2000; Fackenthal and
Olopade, 2007; Ferla et al, 2007), a fact that allows more cost-
effective screening of individuals with low mutation probability.
Testing could thus be made accessible to more women. From such
broader studies, it has emerged that many women found to carry a
mutation do not have a documented previous family history of the
disease.
We have shown in our previous work on the BRCA1 and BRCA2
mutation spectrum of the Greek population that four BRCA1
mutations account for 54% of all mutations detected in both genes,
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swhereas the rest are unique or low-frequency mutations, reflecting
the population’s genetic heterogeneity (Konstantopoulou et al,
2008). As our previous studies involved individuals with medium
to strong family history, our aim here is to expand the population
screened to breast cancer patients independently of their family
history of breast or ovarian cancer. A hospital-based cohort of 987
unselected breast cancer cases was analysed to determine the
frequency of the four most common mutations of the BRCA1 gene.
In that way, a population-specific, cost-effective, mini protocol for
genetic testing of hereditary breast cancer is applied to a wider
population setting and is evaluated for clinical usefulness. As an
early age at breast cancer onset is generally considered an
indicator of genetic susceptibility, it is interesting to assess
whether and in what degree mutation frequencies differ between
unselected cases and cases with disease onset before age 40.
MATERIALS AND METHODS
Patients
Screening for the four BRCA1 mutations was performed in 987
unselected female breast cancer patients with histologically
verified diagnosis, regardless of family history. The samples were
collected from several major hospitals in collaboration with the
Hellenic Cooperative Oncology Group (HECOG), representing
major geographical areas of Greece, such as Athens metropolitan
area, Thessaloniki, Ioannina, Patras, and Crete (Chania). The study
was approved by ethics and research committees of the hospitals
and was in agreement with the 1975 Helsinki statement, revised in
1983. Informed consent was obtained from all individuals before
genetic analysis was performed. The patients’ mean age of breast
cancer diagnosis was 53.9 years, ranging from 20 to 87 years old.
Our cohort included 140 patients with early-onset (o40 years)
breast cancer (14.19% of the total), whereas 382 patients (38.66%)
were diagnosed before the age of 50. Among the 987 patients
tested, 6 have developed bilateral breast cancer (0.6%), 8 have
developed both breast and ovarian cancer (0.8%), and 10 have
developed both breast and another type of cancer (1.0%). Breast
and/or ovarian cancer family history was reported by 111 patients
(11%). The minimum criterion to classify a patient as having
family history was one additional first- or second-degree relative
with breast cancer diagnosed before 50 years or ovarian cancer at
any age. Family history was obtained after an interview with each
patient. Once a mutation was confirmed in an independent blood
sample, results were communicated to patients by the Oncology
units participating in the HECOG network. For patients found to
be carriers, there were ensuing counselling efforts.
Mutation detection
Genomic DNA was extracted from peripheral blood lymphocytes
using a standard chloroform–isoamyl alcohol protocol. The
quantity and the quality of the DNA samples was determined by
UV absorbance using a NanoDrop 1000 (Thermo Fisher Scientific,
MA, USA) and agarose gel electrophoresis. Detection of the BRCA1
c.5266dupC (5382insC) mutation was performed using a pre-
viously described mutagenically separated polymerase chain
reaction (PCR) assay (Chan et al, 1999). The BRCA1 G1738R
mutation was detected using an RFLP-based method as previously
described in Anagnostopoulos et al (2008). To detect the genomic
rearrangements involving BRCA1 exons 20 and 24, we used
diagnostic PCR primers as described in Armaou et al (2007). In all
cases, PCR amplifications were performed in a Veriti 96-Well
Thermal Cycler (Applied Biosystems, Foster City, CA, USA). PCR
products were electrophoresed through 2.5% agarose gel and
visualised by ethidium bromide staining. To confirm each detected
mutation, we directly sequenced PCR products using an ABI
PRISM Dye Deoxy Terminator Kit v3.1 (Applied Biosystems) in
ABI 310 Genetic Analyzer (PerkinElmer, Applied Biosystems),
according to manufacturer’s instructions. Primer sequences and
protocols are available upon request.
RESULTS
We have screened 987 samples from unselected breast cancer
patients for the four most common BRCA1 mutations in Greece:
c.5266dupC (5382insC), G1738R (c.5212G4A), the 3.2kb deletion
of exon 20 (c.5256_5277þ3179del3200), and the 4.4kb deletion of
exon 24 (c.5468-285_5592þ4019del4429_insCACAG).
The distribution of the age of onset among all patients studied
and among patients with family history is shown in Figure 1.
Comparison of the two categories clearly shows a much earlier
disease onset in the latter group, with the majority developing
breast cancer before 50 years. The mean age of diagnosis for
patients with family history was 46.3 years, eight years lower than
that for the whole cohort (53.9 years).
Twenty-six patients (2.6, 95% CI 1.6–3.6%) were found to carry
one of the four BRCA1 mutations presented in this study. Mutation
c.5266dupC (5382insC) was detected in 13 breast cancer patients
(1.3, 95% CI 0.6–2.0%), the exon 24 deletion in 6 patients (0.6,
95% CI 0.1–1.1%), the Greek founder G1738R in 4 patients
(0.4, 95% CI 0.01–08%), and the exon 20 deletion in 3 patients
(0.3, 95% CI 0.0–0.8%). Table 1 summarises disease and family
history characteristics of the 26 mutation carriers.
Among carriers, the mean age of diagnosis was 42.5 years (range
28–61 years), more than a decade lower than the 53.9 years mean
age of onset for the whole cohort. Furthermore, 54% of the carriers
(14 out of 26) belonged to the ‘early-onset’ group (o40 years)
compared to 14% of the whole cohort. Breast and/or ovarian
cancer family history was reported by 17 out of 26 carriers (65.4%)
compared to 11% of all consecutive breast cancer patients
screened.
It is noteworthy that 10% (95% CI 5.0–15.0%) of all early-onset
patients carry one of the four BRCA1 mutations screened, a
fourfold increase from the frequency corresponding to the whole
cohort (2.6%).
DISCUSSION
In the present study, we have identified 26 carriers of a BRCA1
germ-line mutation among a hospital-based series of 987 breast
cancer patients unselected for family history, specifically screened
for the four most common BRCA1 mutations in the Greek
population. This is the first report of an effort to provide a reliable
frequency of those mutations in Greek breast cancer patients,
regarding unselected cases as well as early-onset (below 40 years)
cases.
Most population studies include cases selected for strong family
history of cancer. These have estimated the prevalence of BRCA1
and BRCA2 mutations in such high-risk families from 20 to 67%
((Shih et al, 2000; Fackenthal and Olopade, 2007; Palma et al,
2008), and numerous others), where variation is mainly due to
study design and population genetic pool, that is founder
populations tend to present higher frequencies. There are also
numerous studies with populations selected for age of onset. The
frequency of BRCA1 and BRCA2 mutations in these studies again
varies according to study design (cohort, age that is considered
‘early onset’, mutation screening techniques) and population. For
ages of onset between 35 and 45 years and for Western populations
with no strong founder effects, mutation frequency has been
estimated from 6 to 13% for both genes (Peto et al, 1999; Anglian
Breast Cancer Study Group, 2000; Malone et al, 2000; Syrjakoski
et al, 2000; Loman et al, 2001; de Sanjose et al, 2003; Bonadona
et al, 2005; Lubinski et al, 2006). Our findings of a prevalence of
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s10% for the four common BRCA1 mutations in Greece in early-
onset cases (o40 years) are broadly consistent with the estimates
from the previous studies.
Less is known about the prevalence of BRCA mutations in the
general population or even in unselected breast cancer cases. Most
available data originate from founder populations only screened
for their founder mutations (Abeliovich et al, 1997; Thorlacius
et al, 1998; Warner et al, 1999). The limited number of studies
concerning unselected cases in populations with genetic hetero-
geneity report a frequency of 1.8–4.7% for both genes (for a
review, see Fackenthal and Olopade (2007)). For BRCA1 only, a
mutation frequency of 0.4% is found in Finnish (Syrjakoski et al,
2000), 2.1% in Dutch (Papelard et al, 2000), 3% in Polish (Gorski
et al, 2005), o1% in Swedish (Margolin et al, 2004), 1.5% in
Brazilian (Gomes et al, 2007), and 2.4–3.5% in US unselected
breast cancer patients (Newman et al, 1998; Malone et al, 2006;
John et al, 2007). In our present study, we report a total frequency
of 2.6% for the four BRCA1 mutations screened. This result is the
minimum estimate and most likely an underestimate of the true
frequency of all BRCA1 mutations in Greek breast cancer patients.
The Greek BRCA1 and BRCA2 mutation spectrum, as emerged
from full screening in high-risk patients, consists of a total of 26
different mutations, 15 in BRCA1 and 11 in BRCA2. Of these, only
four BRCA1 mutations are found in 54% of the families carrying
either a BRCA1 or a BRCA2 mutation and in 73% of the families
carrying a BRCA1 mutation (Konstantopoulou et al, 2008). An
extrapolation of the present results in an effort to deduce the
true frequency of all BRCA1 and BRCA2 mutations in unselected
breast cancer patients would suggest that about 4.8% of all
Greek breast cancer patients can be carriers of a BRCA1 or BRCA2
mutation, as the four mutations screened here (2.6% frequency)
only represent 54% of the BRCA1/2-positive high-risk families.
In the same line, 18% of all early-onset patients (o40 years)
can carry either a BRCA1 or a BRCA2 mutation, given the
frequency of 10% found here for the four common BRCA1
mutations screened. Of the 111 breast cancer patients among our
cohort that reported a family history of breast and/or ovarian
cancer, 17 have been found to carry one of the four BRCA1
mutations (15.3%). The lower frequency than the previously
reported of 20% can be explained by our use of less strict criteria
to define family history and because screening was limited to the
four common mutations.
The two categories in our cohort – that of patients reporting
family history and that with early-onset (o40 years) of the disease
– are interdependent, that is more than one-third (42 out of 111,
38%) of patients with family history are also early-onset cases (see
also Figure 1); vice versa, one-third of early-onset cases (42 out of
140, 30%) have family history. Of the 42 patients belonging to both
groups, 11 carried a mutation (26%). Table 2 summarises mutation
frequencies for the various categories among our cohort.
Half of the carriers identified in the present study (13 out of 26)
have BRCA1 mutation c.5526dup (5382insC). According to
previously published results, this mutation accounts for 31% of
the BRCA1 and BRCA2 mutations identified in Greek familial
breast/ovarian cancer patients (Ladopoulou et al, 2002; Konstan-
topoulou et al, 2008). As haplotype analysis has shown, BRCA1
c.5526dup (5382insC) is a ‘founder’ mutation that originated from
the Baltic area and has spread worldwide, but is more prevalent in
eastern European and Ashkenazi populations (Neuhausen et al,
1996; Szabo and King, 1997; Hamel et al, 2006; da Costa et al,
2008). The frequency of the mutation revealed here (1.3%) is
consistent with previous studies performed also in unselected
breast cancer patients. A frequency of 1% is reported in Germany
(Backe et al, 1999), of 1.3% in Brazil (Gomes et al, 2007), of 2.1% in
Poland (Gorski et al, 2005), of 3.7–4% in Russia (Sokolenko et al,
2006; Bermisheva et al, 2008), and of 2.5–3.8% for Ashkenazim
living in the United States (King et al, 2003) and Canada
(Satagopan et al, 2001). Contrary to the case of c.5526dupC, the
other three BRCA1 mutations screened here have been found only
in Greek patients.
The present findings have important implications for determin-
ing the policy for BRCA1 and BRCA2 mutation testing in the Greek
population and populations with similar genetic background. It is
currently widely accepted that women who fulfil certain criteria
based on family history alone or in combination with age of onset
should be directed towards BRCA1 and BRCA2 genetic testing. The
complexities of the particular test prohibit its recommendation to
wider targets, such as all breast cancer patients or even the whole
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Figure 1 Age of onset distribution among the 987 consecutive breast cancer patients tested. Black bars depict distribution of the total number of patients,
whereas grey bars include only patients with family history.
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spopulation. However, many mutation carriers who do not fulfil
screening criteria have been identified before. We have discovered
among our cohort six mutation carriers with no reported family
history and with later onset of the disease (Table 2). These cases
would have been missed if commonly applied (e.g. two cases of
breast cancer before age 50) screening criteria were used. As
BRCA1 mutations are highly penetrant and de novo formation is
extremely rare, the following factors should be considered as an
explanation and taken into account when evaluating patients for
referral to genetic testing: misreported family history due to lack of
knowledge or unwillingness to share information, limited family
structure, greater prevalence of male family members, paternal
inheritance, also for Greece the lack of a National Cancer Registry.
To address this matter, we believe that the simplified BRCA1
screening for the four most prevalent Greek mutations designed
and employed here should be offered to more women with breast
cancer, especially those with an early disease onset and ideally to
all breast cancer patients. Furthermore, we propose that all early-
onset patients should be directed towards full BRCA1 and BRCA2
screening as the true frequency of mutations in this group as
indicated by our results could be close to 20%.
In conclusion, our results indicate that 2.6% of the Greek
patients developing breast cancer independently of age or family
history and 10% of Greek patients developing breast cancer before
age 40 carry one of four common Greek BRCA1 mutations. This
finding shows the necessity of a new simplified and focused genetic
Table 2 Representation and carrier frequency of various breast cancer patient categories in our screening cohort
Patient category
% in cohort
(n¼987)
% of carriers in each
category/95% CI
% of 5382insC carriers
in each category
% in carriers
(n¼26)
Total 100% (n¼987) 2.6 (26/987)/1.6–3.6% 1.3 (13/987) 100 (n¼26)
Family history
a 11 (n¼111) 15.3 (17/111)/8.6–22.0% 8.1 (9/111) 65.4 (n¼17)
Early onset (o40 years) 14.19 (n¼140) 10 (14/140)/5.0–15.0% 7.1 (10/140) 54 (n¼14)
Family history and early-onset (o40 years) 4.25 (n¼42) 26.2 (11/42)/12.9–39.5% 19 (8/42) 42.3 (n¼11)
Ovarian cancer
b 2.13 (n¼21) 47.6 (10/21)/26.3–69.0% 23.8 (5/21) 38.5 (n¼10)
No family history, onset 441 years 79 (n¼781) 0.77 (6/781)/0.2–1.4% 0.26 (2/781) 23.1 (n¼6)
aBy criteria stated in text.
bPersonal or family history.
Table 1 Disease history of the 26 breast cancer patients found to carry a BRCA1 germ-line mutation
Mutation Patient no. Age of onset
Family history of breast and
ovarian cancer (age of onset) Comments/other cancers
c.5266dupC
(5382insC)
363 34 Two cousins (p) BrCa52 Father CRC74, sister CRC, uncle (p) stomach ca50
364 33 Sister BrCa37
365 33 Aunt (p) OvCa53, Aunt (p) OvCa54
366 35 Mother OvCa45
368 39 NO
369 36 Mother OvCa, aunt (p) BrCa Grandmother (m) CRC or stomach ca
370 58 Sister BrCa and OvCa Mother gynaecological ca (details not known), father
haematological ca
371 31 Aunt (m) BrCa or OvCa
387 37 Sister BrCa32, cousin (m) BrCa Father pancreatic ca
412 57 No
454 40 Mother BrCa68, mother’s sister BrCa52,
mother’s sister BrCa50, sister BrCa42
552 49 No
578 36 No
Exon 24
deletion
a
284 52 Proband OvCa52, mother’s sister BrCa
332 28 Proband OvCa31 Father Hodgkin’s53, grandmother (p) CRC, grandfather
(m) ca urinary bladder, mother’s brother Hodgkin’s78
382 29 Mother BrCa32 and BrCa42 Father brain ca55
440 69 Proband OvCa48
442 39 Mother OvCa52, cousin (m) BrCa50,
mother’s sister BrCa
Grandmother (m) uterine ca, aunt (m) uterine ca52,
cousin (m) uterine ca52
468 39 No
G1738R
b 373 47 Sister BrCa27, father’s sister bilateral
BrCa o50, father’s sister BrCa47, father’s
sister BrCa50
Proband previously had BrCa39, father CRC74
374 61 No
375 57 No
466 46 Mother’s sister BrCa 47
Exon 20
deletion
a
351 43 No
428 58 Proband OvCa56, cousin (p) BrCa Mother CRC, father liver ca, cousins (p) gynaecological
ca (details not known), cousin (p) lung ca, father’s
brother ca larynx, father’s sister ca unknown primary
441 51 No
Abbreviations: ca, cancer; (m), maternal side; (p), paternal side; BrCa, breast cancer; OvCa, ovarian cancer; CRC, colorectal cancer; number after condition indicates age of onset
(where known).
aDescribed in Armaou et al (2007).
bGreek founder mutation (Anagnostopoulos et al, 2008).
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sscreening approach reaching to a wider population target.
Our results also imply that recommendation of full
screening of the BRCA1 and BRCA2 genes, and even additional
predisposing genes, to all breast cancer patients should remain the
ultimate goal as new technologies emerge that can lower
the cost and effort involved. This point gains additional weight
under the view of new personalised therapeutics evolving in the
field of oncology.
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